Lumenis Launches OptiLIFT, Device to Address Lower Lid Laxity and Impaired Blinking

Lumenis announced the launch of OptiLIFT, a new device that uses Dynamic Muscle Stimulation technology (DMSt) to tone facial muscles to improve lower lid laxity and impaired blinking. OptiLIFT marks one of the first treatment options that eliminates the need for surgery. 

“OptiLIFT enables providers to address lower lid laxity and impaired blinking non-surgically, delivering meaningful results for patients while offering a unique opportunity for practice differentiation,” Itay Mayer, Chief Commercial Officer of Lumenis said. “We look forward to collaborating with providers to close the gap in their practices, bring this new solution to the market, and elevate patient care.”

Lower lid laxity is highly prevalent and is a natural part of the aging process. In part, it is caused by weakening of the orbicularis oculi muscle. As periorbital muscles weaken with age, the eyelids lose their structural support, causing lid laxity and impaired blinking. One study revealed that more than 60% of dry eye patients suffer from impaired lid closure.

OptiLIFT’s DMSt works by activating the periorbital muscles with electrical impulses, causing them to tighten and increase their tone. It is built with a radio frequency component that precisely delivers heat to skin layers to enhance collagen formation. OptiLIFT also has an optional micro-needling upgrade, which uses ultra-thin needles and a double radiofrequency mechanism. 

A new clinical study found OptiLIFT restores muscle tone to significantly improve in function of the lower eyelid and blinking quality. Led by James Chelnis, MD, an ophthalmic plastic and reconstructive surgeon at Manhattan Face & Eye, OptiLIFT demonstrated a reduction in lid laxity by at least 75%, an improvement in blinking quality by at least 70%, and a significant 286% increase in tear break-up time (TBUT), according to Lumenis. 

“OptiLIFT finally offers us a non-surgical solution that is effective and comfortable for patients, without any downtime,” Dr. Chelnis said. “Our clinical study revealed remarkable outcomes for patients that highlight the true value of OptiLIFT.”

Lumenis will exhibit OptiLIFT at the upcoming Vision Expo East in Orlando, Florida, later this month.